Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead And Roche Resolve Tamiflu Licensing Dispute

This article was originally published in The Pink Sheet Daily

Executive Summary

Increased antiviral demand in the face of seasonal flu and the threat of pandemic avian flu leads the firms to settle arbitration over a manufacturing and commercialization agreement.

You may also be interested in...



Gilead Acquisition Of Corus Adds Respiratory Disease Candidate

Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.

Gilead Acquisition Of Corus Adds Respiratory Disease Candidate

Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.

Gilead Files To Break Tamiflu Agreement With Roche, Citing Breach Of Contract

Roche will have a chance to address Gilead's claims before their partnership for the flu antiviral is terminated. Gilead claims Roche breached the contract by lessening its marketing efforts, neglecting manufacturing quality management, and inaccurately calculating royalty payments.

Topics

UsernamePublicRestriction

Register

PS061269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel